Outlook Therapeutics Inc Share Price Today: Live Updates & Key Insights

Outlook Therapeutics Inc share price today is $0.3504, up 4.43%. The stock opened at $0.3429 against the previous close of $0.3362, with an intraday high of $0.37 and low of $0.33505.

Outlook Therapeutics Inc Share Price Chart

Outlook Therapeutics Inc

us-stock
To Invest in {{usstockname}}
us-stock

Outlook Therapeutics Inc Share Price Performance

$0.3504 0.0443(4.43%) OTLK at 23 Mar 2026 02:38 PM Biotechnology
Lowest Today 0.33505
Highest Today 0.37
Today’s Open 0.3429
Prev. Close 0.3362
52 Week High 3.39
52 Week Low 0.29
Day’s Range: Low 0.33505 High 0.37
52-Week Range: Low 0.29 High 3.39
1 day return -
1 Week return -2.48
1 month return -14.12
3 month return -81.13
6 month return -64.04
1 year return -76.9
3 year return -98.34
5 year return -99.29
10 year return -

Outlook Therapeutics Inc Institutional Holdings

Schonfeld Strategic Advisors LLC 2.94

Vanguard Group Inc 1.76

Vanguard Total Stock Mkt Idx Inv 1.14

BlackRock Inc 0.45

GILPIN WEALTH MANAGEMENT, LLC 0.43

Geode Capital Management, LLC 0.38

Vanguard Institutional Extnd Mkt Idx Tr 0.38

Marshall Wace Asset Management Ltd 0.36

Abante Quant Value FI 0.30

Susquehanna International Group, LLP 0.21

Millennium Management LLC 0.20

Fidelity Extended Market Index 0.19

Blackrock Extended Mkt Fund CF 0.15

Commonwealth Equity Services Inc 0.14

Jane Street Group LLC 0.13

Extended Equity Market Fund K 0.13

Bank of America Corp 0.11

SIMPLEX TRADING, LLC 0.11

State Street Corp 0.09

Scotia Capital Inc 0.09

iShares Micro-Cap ETF 0.09

Fidelity Total Market Index 0.07

LVW Advisors, LLC 0.06

UBS Group AG 0.06

NT Ext Equity Mkt Idx Fd - L 0.06

Goldman Sachs Absolute Ret Trckr Instl 0.05

The Goldman Sachs Group Inc 0.05

Fidelity Series Total Market Index 0.05

Vontobel Holding Ltd. 0.05

Group One Trading, LP 0.04

Spartan Extended Market Index Pool F 0.04

Christensen King & Associates Investment Services Inc 0.03

Spartan Total Market Index Pool G 0.03

Vanguard Instl Ttl Stck Mkt Idx Tr 0.02

NT Ext Equity Mkt Idx Fd - NL 0.02

NT Ext Eq Mkt Indx Fd DC Lending Tier 5 0.02

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.02

Extended Equity Market Fund M 0.01

Fidelity Nasdaq Composite Index 0.01

Vanguard U.S. Eq Idx £ Acc 0.01

Outlook Therapeutics Inc Market Status

Strong Buy: 4

Buy: 1

Hold: 1

Sell: 0

Strong Sell: 0

Outlook Therapeutics Inc Fundamentals

Market Cap 29.16 M

PB Ratio 10.1912

PE Ratio 0.0

Enterprise Value 56.14 M

Total Assets 18584183.00 M

Volume 1785939

Outlook Therapeutics Inc Company Financials

Annual Revenue FY25:1413535 1.4M, FY24:170124 0.2M, FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M

Annual Profit FY25:657205 0.7M, FY24:85062 0.1M, FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M

Annual Net worth FY25:-62424863 -62.4M, FY24:-75366714 -75.4M, FY23:-58983000 -59.0M, FY22:-66052264 -66.1M, FY21:-53163000 -53.2M

Quarterly Revenue Q4/2025:-1208000 -1.2M, Q3/2025:-91787 -0.1M, Q2/2025:1505322 1.5M, Q1/2025:0 0.0M, Q4/2024:170124 0.2M

Quarterly Profit Q4/2025:-1238000 -1.2M, Q3/2025:-1008302 -1.0M, Q2/2025:1065507 1.1M, Q1/2025:-29102 -0.0M, Q4/2024:170124 0.2M

Quarterly Net worth Q4/2025:-23058000 -23.1M, Q3/2025:-13292769 -13.3M, Q2/2025:-20152502 -20.2M, Q1/2025:-46357000 -46.4M, Q4/2024:17377614 17.4M

About Outlook Therapeutics Inc & investment objective

Company Information Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. Outlook Therapeutics, Inc. was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

Organisation Biotechnology

Employees 17

Industry Biotechnology

CEO Mr. Robert Charles Jahr

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Outlook Therapeutics Inc FAQs

What is the share price of Outlook Therapeutics Inc today?

The current share price of Outlook Therapeutics Inc is $0.3504.

Can I buy Outlook Therapeutics Inc shares in India?

Yes, Indian investors can buy Outlook Therapeutics Inc shares by opening an international trading and demat account with Motilal Oswal.

How to buy Outlook Therapeutics Inc shares in India?

You can easily invest in Outlook Therapeutics Inc shares from India by:

Can I buy fractional shares of Outlook Therapeutics Inc?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Outlook Therapeutics Inc?

Outlook Therapeutics Inc has a market cap of $29.16 M.

In which sector does Outlook Therapeutics Inc belong?

Outlook Therapeutics Inc operates in the Biotechnology sector.

What documents are required to invest in Outlook Therapeutics Inc stocks?

To invest, you typically need:

What is the PE and PB ratio of Outlook Therapeutics Inc?

The PE ratio of Outlook Therapeutics Inc is N/A and the PB ratio is 10.19.